The oxytocin receptor signalling system and breast cancer: a critical review.
Animals
Antineoplastic Agents
/ pharmacology
Breast Neoplasms
/ drug therapy
Cell Transformation, Neoplastic
/ drug effects
Chemoprevention
Disease Management
Disease Models, Animal
Disease Susceptibility
Drug Evaluation, Preclinical
Female
Gene Expression Regulation, Neoplastic
Humans
Ligands
Molecular Targeted Therapy
Oxytocin
/ analogs & derivatives
Receptors, Estrogen
/ metabolism
Receptors, Oxytocin
/ genetics
Signal Transduction
/ drug effects
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
29
04
2020
accepted:
29
07
2020
revised:
21
07
2020
pubmed:
13
8
2020
medline:
1
12
2020
entrez:
13
8
2020
Statut:
ppublish
Résumé
Breast cancer is making up one-quarter of all new female cancer cases diagnosed worldwide. Breast cancer surgeries, radiation therapies, cytotoxic chemotherapies and targeted therapies have made significant progress and play a dominant role in breast cancer patient management. However, many challenges remain, including resistance to systemic therapies, tumour recurrence and metastasis. The cyclic neuropeptide oxytocin (OT) elicits a plethora of biological responses via the oxytocin receptor (OTR) in both the central and peripheral nervous system, including social bonding, stress, maternal behaviour, sexual activity, uterus contraction, milk ejection and cancer. As a typical member of the G protein-coupled receptor family, OTR represents also an intriguing target for cancer therapy. There is emerging evidence that OTR plays a role in breast cancer development and progression, and several breast cancer cell lines express OTR. However, despite supporting evidence that OT lowers breast cancer risks, its mechanistic role in breast cancer development and the related signalling pathways are not fully understood. Here, we review the current knowledge of the OT/OTR signalling system in healthy breast tissue as well as in breast cancer, and discuss OTR as a potential therapeutic target for breast cancer management.
Identifiants
pubmed: 32782397
doi: 10.1038/s41388-020-01415-8
pii: 10.1038/s41388-020-01415-8
pmc: PMC7483001
mid: EMS95121
doi:
Substances chimiques
Antineoplastic Agents
0
Ligands
0
Receptors, Estrogen
0
Receptors, Oxytocin
0
Oxytocin
50-56-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5917-5932Subventions
Organisme : European Research Council
ID : 714366
Pays : International
Organisme : Austrian Science Fund FWF
ID : I 3243
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 32109
Pays : Austria
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics 2016. CA Cancer J Clin. 2016;66:271–89.
pubmed: 27253694
Siegel RL, Miller KD, Jemal A. Cancer statistic, 2020. CA Cancer J Clin. 2020;70:7–30.
pubmed: 31912902
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629–83.
pubmed: 11274341
Jurek B, Neumann ID. The oxytocin receptor: from intracellular signaling to behavior. Physiol Rev. 2018;98:1805–908.
pubmed: 29897293
Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science. 2008;322:900–4.
pubmed: 18988842
Gruber CW, Koehbach J, Muttenthaler M. Exploring bioactive peptides from natural sources for oxytocin and vasopressin drug discovery. Future Med Chem. 2012;4:1791–8.
pubmed: 23043476
Koehbach J, Stockner T, Bergmayr C, Muttenthaler M, Gruber CW. Insights into the molecular evolution of oxytocin receptor ligand binding. Biochem Soc Trans. 2013;41:197–204.
pubmed: 23356283
pmcid: 3634130
Lerman B, Harricharran T, Ogunwobi OO. Oxytocin and cancer: an emerging link. World J Clin Oncol. 2018;9:74–82.
pubmed: 30254962
pmcid: 6153127
Imanieh MH, Bagheri F, Alizadeh AM, Ashkani-Esfahani S. Oxytocin has therapeutic effects on cancer, a hypothesis. Eur J Pharmacol. 2014;741:112–23.
pubmed: 25094035
Strunecka A, Hynie S, Klenerova V. Role of oxytocin/oxytocin receptor system in regulation of cell growth and neoplastic processes. Folia Biol (Praha). 2009;55:159–65.
Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004;11:871–85.
pubmed: 15613460
Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, et al. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology. 2001;142:1130–6.
pubmed: 11181528
Petersson M, Lagumdzija A, Stark A, Bucht E. Oxytocin stimulates proliferation of human osteoblast-like cells. Peptides. 2002;23:1121–6.
pubmed: 12126740
Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, et al. Oxytocin is a growth factor for Kaposi’s sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res. 2002;62:2406–13.
pubmed: 11956104
Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int J Cancer. 1998;77:695–700.
pubmed: 9688301
Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G. Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. J Pathol. 2000;190:470–7.
pubmed: 10699997
Busnelli M, Rimoldi V, Vigano P, Persani L, Di Blasio AM, Chini B. Oxytocin-induced cell growth proliferation in human myometrial cells and leiomyomas. Fertil Steril. 2010;94:1869–74.
pubmed: 20056210
Morita T, Shibata K, Kikkawa F, Kajiyama H, Ino K, Mizutani S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer. 2004;109:525–32.
pubmed: 14991573
Xu H, Fu S, Chen Q, Gu M, Zhou J, Liu C, et al. The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer. Oncotarget. 2017;8:31215–26.
pubmed: 28415720
pmcid: 5458202
Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate. 2007;67:1132–42.
pubmed: 17492653
Petersson M. Opposite effects of oxytocin on proliferation of osteosarcoma cell lines. Regulatory Pept. 2008;150:50–4.
Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Clapp RW, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med. 1994;330:81–7.
pubmed: 8259187
Collaborative Group on Hormonal Factors in Breast C. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95.
Li T, Wang P, Wang SC, Wang YF. Approaches mediating oxytocin regulation of the immune system. Front Immunol. 2016;7:693.
pubmed: 28119696
Wang P, Yang HP, Tian S, Wang L, Wang SC, Zhang F, et al. Oxytocin-secreting system: a major part of the neuroendocrine center regulating immunologic activity. J Neuroimmunol. 2015;289:152–61.
pubmed: 26616885
Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol. 2012;1:533–57.
pubmed: 22844349
pmcid: 3404495
Desprez PY, Lin CQ, Thomasset N, Sympson CJ, Bissell MJ, Campisi J. A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol Cell Biol. 1998;18:4577–88.
pubmed: 9671467
pmcid: 109043
Brisken C, O’Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2010;2:a003178.
pubmed: 20739412
pmcid: 2982168
Berryhill GE, Trott JF, Hovey RC. Mammary gland development-It’s not just about estrogen. J Dairy Sci. 2016;99:875–83.
pubmed: 26506542
Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia. 2002;7:49–66.
pubmed: 12160086
Hassiotou F, Geddes D. Anatomy of the human mammary gland: current status of knowledge. Clin Anat. 2013;26:29–48.
pubmed: 22997014
Benson GK, Folley SJ. The effect of oxytocin on mammary gland involution in the rat. J Endocrinol. 1957;16:189–201.
pubmed: 13491749
ÔTa K, Yokoyama A, Shinde Y. Effects of administration of oxytocin and prolactin on nucleic acids and phosphoprotein contents of mammary glands in lactating rats. Nature. 1962;195:77.
Yokoyama A, Ota K. Effect of oxytocin replacement on lactation in rats bearing hypothalamic lesions. Endocrinologia Japonica. 1959;6:268–76.
pubmed: 13846559
Mccann SM, Mack R, Gale C. The possible role of oxytocin in stimulating the release of prolactin. Endocrinology. 1959;64:870–89.
pubmed: 13652904
Cassoni P, Marrocco T, Sapino A, Allia E, Bussolati G. Oxytocin synthesis within the normal and neoplastic breast: first evidence of a local peptide source. Int J Oncol. 2006;28:1263–8.
pubmed: 16596243
Sapino A, Macri L, Tonda L, Bussolati G. Oxytocin enhances myoepithelial cell differentiation and proliferation in the mouse mammary gland. Endocrinology. 1993;133:838–42.
pubmed: 8344220
Wagner KU, Young WS 3rd, Liu X, Ginns EI, Li M, Furth PA, et al. Oxytocin and milk removal are required for post-partum mammary-gland development. Genes Funct. 1997;1:233–44.
pubmed: 9678900
Cassoni P, Sapino A, Negro F, Bussolati G. Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Arch. 1994;425:467–72.
pubmed: 7850070
Murrell TG. The potential for oxytocin (OT) to prevent breast cancer: a hypothesis. Breast Cancer Res Treat. 1995;35:225–9.
pubmed: 7647345
Mustacchi P. Ramazzini and Rigoni-Stern on parity and breast cancer. Clinical impression and statistical corroboration. Arch Intern Med. 1961;108:639–42.
pubmed: 14477595
Le MG, Bachelot A, Hill C. Characteristics of reproductive life and risk of breast cancer in a case-control study of young nulliparous women. J Clin Epidemiol. 1989;42:1227–33.
pubmed: 2585013
Sugawara Y, Kakizaki M, Nagai M, Tomata Y, Hoshi R, Watanabe I, et al. Lactation pattern and the risk for hormone-related female cancer in Japan: the Ohsaki Cohort Study. Eur J Cancer Prev. 2013;22:187–92.
pubmed: 23358107
Purwanto H, Sadjimin T, Dwiprahasto I. Lactation and the risk of breast cancer. Gan Kagaku Ryoho.2000;27(Suppl 2):474–81.
De Silva M, Senarath U, Gunatilake M, Lokuhetty D. Prolonged breastfeeding reduces risk of breast cancer in Sri Lankan women: a case-control study. Cancer Epidemiol. 2010;34:267–73.
pubmed: 20338838
Robinson VC. Support for the hypothesis that sexual breast stimulation is an ancestral practice and a key to understanding women’s health. Med Hypotheses. 2015;85:976–85.
pubmed: 26386486
Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM. Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987;64:27–31.
pubmed: 3782434
Graf C, Wessely N. Physical activity in the prevention and therapy of breast cancer. Breast Care. 2010;5:389–94.
pubmed: 21494404
pmcid: 3076351
Patel AV, Callel EE, Bernstein L, Wu AH, Thun MJ. Recreational physical activity and risk of postmenopausal breast cancer in a large cohort of US women. Cancer Causes Control. 2003;14:519–29.
pubmed: 12948283
Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994;86:1403–8.
pubmed: 8072034
Landgraf R, Hacker R, Buhl H. Plasma vasopressin and oxytocin in response to exercise and during a day-night cycle in man. Endokrinologie. 1982;79:281–91.
pubmed: 7128545
Jong TR, Menon R, Bludau A, Grund T, Biermeier V, Klampfl SM, et al. Salivary oxytocin concentrations in response to running, sexual self-stimulation, breastfeeding and the TSST: The Regensburg Oxytocin Challenge (ROC) study. Psychoneuroendocrinology. 2015;62:381–8.
pubmed: 26385109
Friedenreich CM. Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res. 2011;188:125–39.
pubmed: 21253795
Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol. 2005;23:3830–42.
pubmed: 15923576
Alizadeh AM, Heydari Z, Rahimi M, Bazgir B, Shirvani H, Alipour S, et al. Oxytocin mediates the beneficial effects of the exercise training on breast cancer. Exp Physiol. 2018;103:222–35.
pubmed: 29143998
Carrera-Gonzalez MP, Ramirez-Exposito MJ, de Saavedra JM, Sanchez-Agesta R, Mayas MD, Martinez-Martos JM. Hypothalamus-pituitary-thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system. Tumour Biol. 2011;32:543–9.
pubmed: 21207221
Ariana M, Pornour M, Mehr SS, Vaseghi H, Ganji SM, Alivand MR, et al. Preventive effects of oxytocin and oxytocin receptor in breast cancer pathogenesis. Per Med. 2019;16:25–34.
pubmed: 30451597
Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 1990;50:7882–6.
pubmed: 2174737
Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Aminopeptidase activities in breast cancer tissue. Clin Chem. 1999;45:1797–802.
pubmed: 10508127
Prevost M, Zelkowitz P, Tulandi T, Hayton B, Feeley N, Carter CS, et al. Oxytocin in pregnancy and the postpartum: relations to labor and its management. Front Public Health. 2014;2:1.
pubmed: 24479112
pmcid: 3902863
Uvnas-Moberg K, Widstrom AM, Werner S, Matthiesen AS, Winberg J. Oxytocin and prolactin levels in breast-feeding women. Correlation with milk yield and duration of breast-feeding. Acta Obstet Gynecol Scand. 1990;69:301–6.
pubmed: 2244461
Iseri SO, Sener G, Saglam B, Gedik N, Ercan F, Yegen BC. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res. 2005;126:73–81.
pubmed: 15916978
Biyikli NK, Tugtepe H, Sener G, Velioglu-Ogunc A, Cetinel S, Midillioglu S, et al. Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism. Peptides. 2006;27:2249–57.
pubmed: 16707192
Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab. 2008;295:E1495–501.
pubmed: 18940936
pmcid: 2603556
Nation DA, Szeto A, Mendez AJ, Brooks LG, Zaias J, Herderick EE, et al. Oxytocin attenuates atherosclerosis and adipose tissue inflammation in socially isolated ApoE-/- mice. Psychosom Med. 2010;72:376–82.
pubmed: 20368478
pmcid: 4784697
Szeto A, Rossetti MA, Mendez AJ, Noller CM, Herderick EE, Gonzales JA, et al. Oxytocin administration attenuates atherosclerosis and inflammation in Watanabe Heritable Hyperlipidemic rabbits. Psychoneuroendocrinology. 2013;38:685–93.
pubmed: 22998949
Sapino A, Cassoni P, Stella A, Bussolati G. Oxytocin receptor within the breast: biological function and distribution. Anticancer Res. 1998;18:2181–6.
pubmed: 9703781
Li D, Ji Y, Zhao C, Yao Y, Yang A, Jin H. et al. OXTR overexpression leads to abnormal mammary gland development in mice. J Endocrinol. 2018;239:121–36.
Gimpl G. Oxytocin receptor ligands: a survey of the patent literature. Expert Opin Therapeutic Pat. 2008;18:1239–51.
PDQ Screening and Prevention Editorial Board. Breast Cancer Screening (PDQ®): Patient Version. 2015 Nov 6. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002-. 2015; https://www.ncbi.nlm.nih.gov/books/NBK65715.2/ .
Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci USA. 2005;102:16096–16101.
pubmed: 16249339
Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci USA. 1996;93:11699–11704.
pubmed: 8876199
Breton C, Di Scala-Guenot D, Zingg HH. Oxytocin receptor gene expression in rat mammary gland: structural characterization and regulation. J Mol Endocrinol. 2001;27:175–89.
pubmed: 11564602
Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab. 2003;14:222–7.
pubmed: 12826328
Ku C-Y, Qian A, Wen Y, Anwer K, Sanborn BM. Oxytocin stimulates myometrial guanosine triphosphatase and phospholipase-C activities via coupling to G alpha q/11. Endocrinology. 1995;136:1509–15.
pubmed: 7895660
Nakano H, Furuya K, Yamagishi S. Synergistic effects of ATP on oxytocin-induced intracellular Ca2+ response in mouse mammary myoepithelial cells. Pflug Arch. 2001;442:57–63.
Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, et al. REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy. CNS Neurosci Ther. 2010;16:e138–56.
pubmed: 20626426
pmcid: 2972642
Sanborn BM, Ku CY, Shlykov S, Babich L. Molecular signaling through G-protein-coupled receptors and the control of intracellular calcium in myometrium. J Soc Gynecol Investig. 2005;12:479–87.
pubmed: 16202924
Svennersten-Sjaunja K, Olsson K. Endocrinology of milk production. Domest Anim Endocrinol. 2005;29:241–58.
pubmed: 15876512
Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol. 2011;2011:350546.
pubmed: 22190926
pmcid: 3235456
Dhondt G, Houvenaghel A, Peeters G, Jochle W. Effect of prostaglandins F2alpha and E2 on milk ejection, blood pressure and blood flow through the mammary artery in the cow. Prostaglandins. 1977;13:1185–99.
pubmed: 887806
Tahara M, Morishige K, Sawada K, Ikebuchi Y, Kawagishi R, Tasaka K, et al. RhoA/Rho-kinase cascade is involved in oxytocin-induced rat uterine contraction. Endocrinology. 2002;143:920–9.
pubmed: 11861513
Strakova Z, Soloff MS. Coupling of oxytocin receptor to G proteins in rat myometrium during labor: Gi receptor interaction. Am J Physiol. 1997;272:E870–6.
pubmed: 9176188
Zhou XB, Lutz S, Steffens F, Korth M, Wieland T. Oxytocin receptors differentially signal via Gq and Gi proteins in pregnant and nonpregnant rat uterine myocytes: implications for myometrial contractility. Mol Endocrinol. 2007;21:740–52.
pubmed: 17170070
Wang YF, Hatton GI. Dominant role of betagamma subunits of G-proteins in oxytocin-evoked burst firing. J Neurosci. 2007;27:1902–12.
pubmed: 17314286
pmcid: 6673548
Amico JA, Rauk PN, Cai HM. Estradiol and progesterone regulate oxytocin receptor binding and expression in human breast cancer cell lines. Endocrine. 2002;18:79–84.
pubmed: 12166628
Ito Y, Kobayashi T, Kimura T, Matsuura N, Wakasugi E, Takeda T, et al. Investigation of the oxytocin receptor expression in human breast cancer tissue using newly established monoclonal antibodies. Endocrinology. 1996;137:773–9.
pubmed: 8593829
Bussolati G, Cassoni P, Ghisolfi G, Negro F, Sapino A. Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast. Am J Pathol. 1996;148:1895–903.
pubmed: 8669475
pmcid: 1861656
Copland JA, Jeng YJ, Strakova Z, Ives KL, Hellmich MR, Soloff MS. Demonstration of functional oxytocin receptors in human breast Hs578T cells and their up-regulation through a protein kinase C-dependent pathway. Endocrinology. 1999;140:2258–67.
pubmed: 10218979
Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A, et al. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res. 2006;4:351–9.
pubmed: 16778082
Cassoni P, Catalano MG, Sapino A, Marrocco T, Fazzari A, Bussolati G, et al. Oxytocin modulates estrogen receptor alpha expression and function in MCF7 human breast cancer cells. Int J Oncol. 2002;21:375–8.
pubmed: 12118334
Keegan BP, Akerman BL, Pequeux C, North WG. Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies. Breast Cancer Res Treat. 2006;95:265–77.
pubmed: 16331351
Cassoni P, Sapino A, Fortunati N, Munaron L, Chini B, Bussolati G. Oxytocin inhibits the proliferation of MDA-MB231 human breast-cancer cells via cyclic adenosine monophosphate and protein kinase A. Int J Cancer. 1997;72:340–4.
pubmed: 9219843
Benavente MA, Bianchi CP, Aba MA. Expression of oxytocin receptors in canine mammary tumours. J Comp Pathol. 2019;170:26–33.
pubmed: 31375156
Cassoni P, Sapino A, Papotti M, Bussolati G. Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas. Int J Cancer. 1996;66:817–20.
pubmed: 8647655
Khori V, Alizadeh AM, Khalighfard S, Heidarian Y, Khodayari H. Oxytocin effects on the inhibition of the NF-kappaB/miR195 pathway in mice breast cancer. Peptides. 2018;107:54–60.
pubmed: 30076862
Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M, et al. The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism. J Biol Chem. 2005;280:16311–8.
pubmed: 15705593
Busnelli M, Sauliere A, Manning M, Bouvier M, Gales C, Chini B. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem. 2012;287:3617–29.
pubmed: 22069312
Bussolati G, Chinol M, Chini B, Nacca A, Cassoni P, Paganelli G. 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”‘-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. Cancer Res. 2001;61:4393–7.
pubmed: 11389066
Chini B, Chinol M, Cassoni P, Papi S, Reversi A, Areces L, et al. Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue. Br J Cancer. 2003;89:930–6.
pubmed: 12942128
pmcid: 2394487
Takeda S, Kuwabara Y, Mizuno M. Metabolic clearance rate of oxytocin in human subjects. Nihon Naibunpi Gakkai Zasshi. 1989;65:182–9.
pubmed: 2767286
Muttenthaler M, Andersson A, Vetter I, Menon R, Busnelli M, Ragnarsson L. et al. Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species. Sci Signal. 2017;10:eaan3398.
pubmed: 29208680
pmcid: 5892705
Gazis D. Plasma half-lives of vasopressin and oxytocin analogs after iv injection in rats. Proc Soc Exp Biol Med. 1978;158:663–5.
pubmed: 693485
Dembinski TC, Leung CK, Shiu RP. Evidence for a novel pituitary factor that potentiates the mitogenic effect of estrogen in human breast cancer cells. Cancer Res. 1985;45:3083–9.
pubmed: 4005846
Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7:659–72.
pubmed: 17721431
Katritch V, Cherezov V, Stevens RC. Diversity and modularity of G protein-coupled receptor structures. Trends Pharm Sci. 2012;33:17–27.
pubmed: 22032986
Neves SR, Ram PT, Iyengar R. G protein pathways. Science. 2002;296:1636–9.
pubmed: 12040175
Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94.
pubmed: 17251915
Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639–50.
pubmed: 12209124
Plested CP, Bernal AL. Desensitisation of the oxytocin receptor and other G-protein coupled receptors in the human myometrium. Exp Physiol. 2001;86:303–12.
pubmed: 11429648
Fay MJ, Du J, Longo KA, North WG. Oxytocin does not induce a rise in intracellular free calcium in human breast cancer cells. Res Commun Mol Pathol Pharmacol. 1999;103:115–28.
pubmed: 10461679
Zhong M, Yang M, Sanborn BM. Extracellular signal-regulated kinase 1/2 activation by myometrial oxytocin receptor involves Galpha(q)Gbetagamma and epidermal growth factor receptor tyrosine kinase activation. Endocrinology. 2003;144:2947–56.
pubmed: 12810550
Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M, et al. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene. 2002;21:1658–67.
pubmed: 11896597
Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, et al. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene. 2003;22:6054–60.
pubmed: 12955084
Klein BY, Tamir H, Welch MG. PI3K/Akt responses to oxytocin stimulation in Caco2BB gut cells. J Cell Biochem. 2011;112:3216–26.
pubmed: 21732407
Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci. 2011;36:457–69.
pubmed: 21764321
pmcid: 3168679
Grotegut CA, Feng L, Mao L, Heine RP, Murtha AP, Rockman HA. beta-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration. Am J Physiol Endocrinol Metab. 2011;300:E468–77.
pubmed: 21139074
Conti F, Sertic S, Reversi A, Chini B. Intracellular trafficking of the human oxytocin receptor: evidence of receptor recycling via a Rab4/Rab5 “short cycle”. Am J Physiol Endocrinol Metab. 2009;296:E532–42.
pubmed: 19126785
Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E, Lopez Bernal A. Internalization and desensitization of the oxytocin receptor is inhibited by Dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol Endocrinol. 2006;20:379–88.
pubmed: 16179383
Jean-Charles PY, Kaur S, Shenoy SKG. Protein-coupled receptor signaling through beta-arrestin-dependent mechanisms. J Cardiovasc Pharmacol. 2017;70:142–58.
pubmed: 28328745
pmcid: 5591062
Cavallaro G, Maniscalco L, Campisi M, Schillaci D, Giammona G. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety. Eur J Pharm Biopharm. 2007;66:182–92.
pubmed: 17182230
Seyedabadi M, Ghahremani MH, Albert PR. Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharm Ther. 2019;200:148–78.
Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. 2018;17:243–60.
pubmed: 29302067
pmcid: 5936084
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473–512.
pubmed: 18655903
Passoni I, Leonzino M, Gigliucci V, Chini B, Busnelli M. Carbetocin is a functional selective Gq agonist that does not promote oxytocin receptor recycling after inducing beta-arrestin-independent internalisation. J Neuroendocrinol. 2016;28.
Kovtun O, Tillu VA, Ariotti N, Parton RG, Collins BM. Cavin family proteins and the assembly of caveolae. J Cell Sci. 2015;128:1269–78.
pubmed: 25829513
pmcid: 4379724
Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen-receptor expression and function in female reproductive disease. Cells. 2019;8:1123.
pmcid: 6830311
Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol. 2014;10:2293–301.
pubmed: 25471040
Renoir JM, Marsaud V, Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol. 2013;85:449–65.
pubmed: 23103568
Nissenson R, Fluoret G, Hechter O. Opposing effects of estradiol and progesterone on oxytocin receptors in rabbit uterus. Proc Natl Acad Sci USA. 1978;75:2044–8.
pubmed: 205880
Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene. 2001;20:1300–6.
pubmed: 11313874
Pandy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harpsoe K, Hauser AS, et al. GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res. 2018;46:D440–6.
pubmed: 29155946
Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, et al. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 1996;397:201–6.
pubmed: 8955347
Kimura T, Makino Y, Saji F, Takemura M, Inoue T, Kikuchi T, et al. Molecular characterization of a cloned human oxytocin receptor. Eur J Endocrinol. 1994;131:385–90.
pubmed: 7921228
Koehbach J, O’Brien M, Muttenthaler M, Miazzo M, Akcan M, Elliott AG, et al. Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc Natl Acad Sci USA. 2013;110:21183–8.
pubmed: 24248349
Aoyagi T, Koshimizu TA, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. Kidney Int. 2009;76:1035–9.
pubmed: 19693000
Bankir L, Bichet DG, Morgenthaler NG. Vasopressin: physiology, assessment and osmosensation. J Intern Med. 2017;282:284–97.
pubmed: 28649750
Cassoni P, Marrocco T, Deaglio S, Sapino A, Bussolati G. Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. Ann Oncol. 2001;12(Suppl 2):S37–9.
pubmed: 11762350
Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–10.
pubmed: 11752295
pmcid: 99122
Wheatley M, Howl J, Yarwood NJ, Hawtin SR, Davies AR, Matthews G, et al. Structure and function of neurohypophysial hormone receptors. Biochem Soc Trans. 1997;25:1046–51.
pubmed: 9388599
Ivell R, Kimura T, Muller D, Augustin K, Abend N, Bathgate R, et al. The structure and regulation of the oxytocin receptor. Exp Physiol. 2001;86:289–96.
pubmed: 11429646
Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183:1113–24.
pubmed: 23993780
pmcid: 5691324
Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol. 2012;24:609–28.
pubmed: 22375852
pmcid: 3490377
Duerrauer L, Muratspahic E, Gattringer J, Keov P, Mendel HC, Pfleger KDG, et al. I8-arachnotocin-an arthropod-derived G protein-biased ligand of the human vasopressin V2 receptor. Sci Rep. 2019;9:19295.
pubmed: 31848378
pmcid: 6917733
Gruber CW, Muttenthaler M. Discovery of defense- and neuropeptides in social ants by genome-mining. PLoS ONE. 2012;7:e32559.
pubmed: 22448224
pmcid: 3308954
Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG, et al. Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides. J Biol Chem. 2008;283:7100–8.
pubmed: 18174156
Di Giglio MG, Muttenthaler M, Harpsoe K, Liutkeviciute Z, Keov P, Eder T, et al. Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide. Sci Rep. 2017;7:41002.
pubmed: 28145450
pmcid: 5286520
de Araujo AD, Mobli M, Castro J, Harrington AM, Vetter I, Dekan Z, et al. Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. Nat Commun. 2014;5:3165.
pubmed: 24476666
Busnelli M, Kleinau G, Muttenthaler M, Stoev S, Manning M, Bibic L, et al. Design and characterization of superpotent bivalent ligands targeting oxytocin receptor dimers via a channel-like structure. J Med Chem. 2016;59:7152–66.
pubmed: 27420737
Muttenthaler M, Andersson A, de Araujo AD, Dekan Z, Lewis RJ, Alewood PF. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J Med Chem. 2010;53:8585–96.
pubmed: 21117646
Garona J, Pifano M, Pastrian MB, Gomez DE, Ripoll GV, Alonso DF. Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clin Exp Metastasis. 2016;33:589–600.
pubmed: 27146156
Benavente MA, Bianchi CP, Imperiale F, Aba MA. Antiproliferative effects of oxytocin and desmopressin on canine mammary cancer cells. Front Vet Sci. 2016;3:119.
pubmed: 28083539
pmcid: 5183597